ESRD

Dialysis Patient Citizens Applauds Kentucky Legislation Expanding Medigap Access

Retrieved on: 
Friday, April 7, 2023
Kentucky House of Representatives, ESRD, Medicaid, Kentucky Senate, Assembly, DPC, Health Management Associates, ALS, Medigap, HB, Dialysis, Medicare, Representative, Patient, 2018 Kentucky Senate Bill 151, Chronic kidney disease, Commonwealth, Transplant, Letter, General assembly, Legislation, Health insurance, Dentistry

WASHINGTON, April 6, 2023 /PRNewswire/ -- Dialysis Patient Citizens (DPC) today applauds the signing of Kentucky bill HB 345, which will ensure access to Medicare Supplement – also called Medigap -- coverage for Kentuckians under 65 living with End-Stage Renal Disease (ESRD) or Amyotrophic Lateral Sclerosis (ALS).

Key Points: 
  • WASHINGTON, April 6, 2023 /PRNewswire/ -- Dialysis Patient Citizens (DPC) today applauds the signing of Kentucky bill HB 345, which will ensure access to Medicare Supplement – also called Medigap -- coverage for Kentuckians under 65 living with End-Stage Renal Disease (ESRD) or Amyotrophic Lateral Sclerosis (ALS).
  • "This legislation is a significant win not only for ESRD and ALS patients across Kentucky, but for their families as well," said Representative Moser.
  • "Kentucky now joins 15 other states that have enacted Medigap access and affordability laws, and 12 others which have an annual open enrollment period for Medigap enrollees to make changes to their coverage," said DPC Board President Andrew Conkling.
  • Previously, Kentucky ESRD patients under 65 did not have access to affordable supplemental "Medigap" coverage to pay the remaining 20 percent.

Dialysis Patient Citizens Celebrates Virginia Legislation Guaranteeing Medigap Access

Retrieved on: 
Friday, March 24, 2023
Kidney disease, ESRD, Medicaid, Virginia Senate, House of Delegates, DPC, Medigap, Dialysis, Medicare, Patient, Commonwealth, Transplant, House, Legislation, Health insurance

WASHINGTON, March 24, 2023 /PRNewswire/ -- Dialysis Patient Citizens (DPC) today celebrates Governor Glenn Youngkin's (R) signing of Virginia bills SB 1409 and HB 1640 into law, guaranteeing access to affordable Medigap coverage for thousands of Virginians under 65 living with end-stage renal disease (ESRD).

Key Points: 
  • WASHINGTON, March 24, 2023 /PRNewswire/ -- Dialysis Patient Citizens (DPC) today celebrates Governor Glenn Youngkin's (R) signing of Virginia bills SB 1409 and HB 1640 into law, guaranteeing access to affordable Medigap coverage for thousands of Virginians under 65 living with end-stage renal disease (ESRD).
  • "Today makes an important milestone for every dialysis patient across Virginia," said House Majority Leader Kilgore.
  • Moving forward, no dialysis patient in the Commonwealth will have to worry about paying unaffordable rates for the treatments that keep them alive.
  • The previous law in Virginia did not guarantee ESRD patients under 65 with access to supplemental "Medigap" coverage to pay the remaining 20 percent.

Dialysis Market Global Market Report 2023: Sector to Reach $148.8 Billion by 2028 at a CAGR of 5.1%

Retrieved on: 
Wednesday, March 15, 2023
Kidney transplantation, Blood, Health, ESRD, Water, Prevalence, CKD, Peritoneal dialysis, Patient, Abdomen, Hypertension, Renal replacement therapy, Chronic kidney disease, COVID-19, Peritoneum, Salt, Kidney disease, Diabetes, Acute kidney injury, Medical device, Pharmaceutical industry, Potash, Dialysis

The growing number of diabetic and hypertension patients along with the increasing incidences of end-stage renal disease (ESRD) are primarily driving the global dialysis market.

Key Points: 
  • The growing number of diabetic and hypertension patients along with the increasing incidences of end-stage renal disease (ESRD) are primarily driving the global dialysis market.
  • Furthermore, the shifting patient preferences from kidney transplantation towards dialysis to reduce health complications and improve quality care are positively influencing the global market.
  • What are the key regions in the global dialysis market?
  • 9. Who are the key players/companies in the global dialysis market?

Fresenius Kidney Care Reunites with Food Is Medicine Coalition on Mission to Expand Access to Medically Tailored Meals

Retrieved on: 
Monday, March 13, 2023
Prevalence, ESRD, Education, MTM, White House conference, Knowledge, United States Department of Health and Human Services, CMS, Diet, Disbursement Acceleration Program, CKD, Medicare, GA, Conference, Dialysis, Centers for Disease Control and Prevention, Exercise, Chronic kidney disease, Quality of life, Research, Patient, Community Health Accreditation Program, Medicine, School health and nutrition services, Food, Diagnosis, Methyltrimethoxysilane, Kidney, Kidney disease, Kidney failure, FIMC, COVID-19, Partnership, Donation, Pharmaceutical industry, Dietary supplement, Medicaid, Health, Hunger

WALTHAM, Mass., March 13, 2023 /PRNewswire/ -- Fresenius Kidney Care, the nation's leader in kidney care services and education, renewed its support for the Food Is Medicine Coalition (FIMC) to help those living with severe illness eat and live better. Fresenius Kidney Care is donating $150,000 to FIMC to expand access to medically tailored meals (MTMs) through the FIMC Accelerator Program and to support the development of an accreditation program to ensure fidelity to the quality standards of the FIMC medically tailored meal model.

Key Points: 
  • Fresenius Kidney Care is donating $150,000 to FIMC to expand access to medically tailored meals (MTMs) through the FIMC Accelerator Program and to support the development of an accreditation program to ensure fidelity to the quality standards of the FIMC medically tailored meal model.
  • March is National Kidney Month, when kidney health advocates such as Fresenius Kidney Care raise awareness about the prevalence of chronic kidney disease (CKD).
  • "We're committed to helping patients living with CKD approach their care holistically, and providing medically tailored meals can help improve their outcomes."
  • With support from Fresenius Kidney Care, FIMC is poised to further drive broader access to medically tailored meals across the country by leveraging this widespread momentum for "food is medicine" interventions.

ExactCare Partners With National Dialysis Provider to Improve Outcomes for Patients With Kidney Disease

Retrieved on: 
Monday, March 6, 2023
CMS, QIP, Medicare, Reconciliation (United States Congress), Renal replacement therapy, Dialysis, Patient, Kidney disease, Centers for Medicare & Medicaid Services, Medication, Polypharmacy, Medicine, SVP, Partnership, Health, Cost, ESRD, PDC, Drug, Pharmaceutical industry, Health insurance

CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- ExactCare, a national medication management and pharmacy care provider for people with chronic medical needs, has partnered with a national dialysis provider to improve medication management for patients with end-stage renal disease (ESRD) receiving renal replacement therapy.

Key Points: 
  • CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- ExactCare, a national medication management and pharmacy care provider for people with chronic medical needs, has partnered with a national dialysis provider to improve medication management for patients with end-stage renal disease (ESRD) receiving renal replacement therapy.
  • Provider Cost Savings: The ExactCare monthly medication review is relayed to the dialysis clinic to support medication reconciliation by a dialysis nurse.
  • This process saves the nurse an average of 28 minutes per patient compared to patients not in the ExactCare program.
  • We are pleased to provide patients this added support to help improve their quality of life.”

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

Retrieved on: 
Monday, March 6, 2023
Tablet, Medicare, Phosphorus, Kidney disease, Center for Medicare and Medicaid Innovation, Dialysis, RA, Hyperphosphatemia, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Patient, ESRD, Food, PD, FDA, LOS, Financial services, Pharmaceutical industry

LOS ALTOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors that will provide up to $130 million in gross proceeds to Unicycive through a private placement that includes initial upfront funding of $30 million.

Key Points: 
  • In conjunction with the financing, Gaurav Aggarwal, M.D., Managing Director of Vivo Capital, will join the Unicycive Board of Directors.
  • We remain on track to file a New Drug Application (NDA) for Renazorb marketing approval with the U.S. Food and Drug Administration (FDA) in mid-year,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive.
  • We are pleased to support Unicycive as it nears NDA submission and prepares to launch Renazorb, a phosphate binder that potently controls phosphate with only three small tablets per day.
  • “If approved, Renazorb may dramatically reduce the pill burden that patients endure with currently available medications.

The National Kidney Foundation and Healthy.io partner to Increase Access to Testing for Detection of Kidney Disease

Retrieved on: 
Wednesday, March 8, 2023
Healthy.io, MD, NKF, Kidney failure, National Kidney Foundation, Kidney disease, Dialysis, CKD, Chronic kidney disease, Hypertension, Partnership, World Kidney Day, African Americans, Patient, Risk, Disease, ESRD, Diabetes, Transport, Urine, ACR, FDA, EGFR, Microalbuminuria, Glomerular filtration rate, Pharmaceutical industry, Multiple minute digitate hyperkeratosis

BOSTON, March 8, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF), a non-profit health organization dedicated to the awareness, prevention, and treatment of kidney disease, and Healthy.io, the global leader in transforming the smartphone camera into a clinical-grade medical device, today announced a new effort to promote detection of chronic kidney disease (CKD). Through their partnership, the NKF and Healthy.io will offer Healthy.io's Minuteful Kidney™ at-home kidney test, free of charge, to people who are at risk for kidney disease. 

Key Points: 
  • Through their partnership, the NKF and Healthy.io will offer Healthy.io's Minuteful Kidney™ at-home kidney test, free of charge, to people who are at risk for kidney disease.
  • "This is particularly concerning when it comes to annual urine testing for kidney disease.
  • campaign aims to raise awareness of the importance of early kidney disease detection," said Joseph Vassalotti, MD, Chief Medical Officer of the National Kidney Foundation.
  • Working to promote kidney health equity for all and increasing access to early detection are top priorities for NKF.

Renalogic Announces Record Growth in 2022 – CKD Management Company Continues to be Category Leader

Retrieved on: 
Tuesday, February 14, 2023
Professional Services, Health, Insurance, Health Insurance, Human Resources, Managed Care, Consulting, ESRD, Taft–Hartley Act, Kidney disease, Transport, CKD, Dialysis, Chronic kidney disease

Renalogic, the leading company helping employers and self-funded health plans fight the human and financial costs of chronic kidney disease (CKD) and end-stage renal disease (ESRD), announced record growth in 2022.

Key Points: 
  • Renalogic, the leading company helping employers and self-funded health plans fight the human and financial costs of chronic kidney disease (CKD) and end-stage renal disease (ESRD), announced record growth in 2022.
  • In 2022, Renalogic added more than 75 new client plans which support more than 150,000 members.
  • These new clients range in size from a plan with a few dozen plan members up to a Fortune 500 company with 50,000 members.
  • “2022 was a great year for our clients and for our company,” said Kevin Weinstein, CEO of Renalogic.

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

Retrieved on: 
Thursday, February 2, 2023
Medication, Conditional, IgA nephropathy, European Commission, Immunoglobulin A, ESRD, United Kingdom, CMA, Kidney disease, MHRA, Civil service commission, UPCR, Patient, European Economic Area, CET, Risk, Person, Health care, EC, Disease, Stada Arzneimittel, CALT, Kidney, Pharmaceutical industry, EEA, Budesonide

STOCKHOLM, Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

Key Points: 
  • STOCKHOLM, Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.
  • The MHRA authorization follows the European Commission (EC) authorization in July of 2022.
  • Calliditas will transfer the CMA to its partner STADA Arzneimittel AG, which is commercializing Kinpeygo in the European Economic Area (EEA) member states, Switzerland and the UK.
  • STADA launched Kinpeygo in its lead launch market, Germany, in October 2022.

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

Retrieved on: 
Thursday, February 2, 2023
Medication, Conditional, IgA nephropathy, European Commission, Immunoglobulin A, ESRD, United Kingdom, CMA, Kidney disease, MHRA, Civil service commission, UPCR, Patient, European Economic Area, CET, Risk, Person, Health care, EC, Disease, Stada Arzneimittel, CALT, Kidney, Pharmaceutical industry, EEA, Budesonide

STOCKHOLM, Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

Key Points: 
  • STOCKHOLM, Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.
  • The MHRA authorization follows the European Commission (EC) authorization in July of 2022.
  • Calliditas will transfer the CMA to its partner STADA Arzneimittel AG, which is commercializing Kinpeygo in the European Economic Area (EEA) member states, Switzerland and the UK.
  • STADA launched Kinpeygo in its lead launch market, Germany, in October 2022.